Extended outcomes from adjuvant accelerated partial breast irradiation show tumor control, breast cosmesis and minimal late toxicity

Long-term (five-year) outcomes of breast cancer patients receiving adjuvant accelerated partial breast irradiation (APBI) after breast-conserving surgery show excellent tumor control and breast cosmesis (cosmetic outcomes) with minimal late toxicity, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology - Biology - Physics (Red...

In patients with invasive breast cancer, external beam radiation therapy reduces risk of subsequent mastectomy

Standard external beam radiation therapy (EBRT) provided a higher breast preservation rate than brachytherapy in women age 66 and older with invasive breast cancer, according to a study published in the February 1, 2014 print edition of the International Journal of Radiation Oncology - Biology - Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology...

New classification system for breast cancers

Breast cancer tumors have long been classified according to their expression of three surface proteins: estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2).These classifications are used to determine best treatments and prognoses, but are not adequate to describe tumor characteristics or compare them to normal breast tissue.

Second breast cancers may be prevented by moderate doses of radiation therapy to unaffected breast

Survivors of breast cancer have a one in six chance of developing breast cancer in the other breast. But a study conducted in mice suggests that survivors can dramatically reduce that risk through treatment with moderate doses of radiation to the unaffected breast at the same time that they receive radiation therapy to their affected breast.

Researchers discover new hormone receptors to target when treating breast cancer

About three-quarters of breast cancers, the most common cancer in women in the U.S., are estrogen hormone dependent. Patients with this type of breast cancer are initially treated with drugs that block estrogen, such as Tamoxifen. However, one-third to half of these patients eventually become resistant to this treatment.